Opinion Polls: Delphi's Polling Place

Hosted by Showtalk

Opinion polls on all subjects. Opinions? Heck yes, we have opinions - but we're *always* nice about it, even when ours are diametrically opposed to yours. Register your vote today!

  • 4378
  • 91582
  • 24


Senior Army Flight Surgeon: Pilots May D   The Healthy You: Health and Fitness Polls

Started Oct-22 by WALTER784; 211 views.

From: WALTER784


Senior Army Flight Surgeon: Pilots May Die In Mid Flight From COVID Vaccines, DoD Abandoned MRI Scan Protocol

Pilots who have been injected with the experimental COVID-19 vaccine may die in mid-flight from the jab’s adverse heart side effects, a senior U.S. Army flight surgeon warns in an affidavit against Biden administration.
According to the recent data published by the Center for Disease Control, the development of myocarditis or pericarditis, a rare heart inflammatory condition, is directly correlated to receiving a second Covid-19 vaccine shot.
CDC safety group chairwoman Dr. Grace Lee admits “clinical presentation of myocarditis cases following vaccination has been distinct, occurring most often within one week after dose two, with chest pain as the most common presentation.”

Senior Army Flight Surgeon: Pilots May Die In Mid Flight From COVID Vaccines, DoD Abandoned MRI Scan Protocol (thegatewaypundit.com)


In reply toRe: msg 2

From: WALTER784


17. On August 23, 2021, the FDA approved Pfizer’s COMIRNATY® (COVID-19 vaccine, mRNA) (“COMIRNATY”), which is legally distinguishable from the BioNTech vaccine as evidenced by the FDA’s COMIRNATY approval announcement published on August 23, 2021.
18. The approval announcement posted on the FDA’s website reads, “On August 23, 2021, the FDA approved the first COVID-19 vaccine. The vaccine has been known as the Pfizer BioNTech COVID-19 Vaccine, and will now be marketed as COMIRNATY, for the prevention of COVID-19 disease in individuals 16 years of age and older.”5
19. As you can see in the above graph, 0.45mg of the 2.25mg (20%) of ingredients contained in a COMIRNATY vial has been sanitized (redacted).
20. While Pfizer’s COMIRNATY approval letter states that its two vaccines share the same formulation, the FDA concedes that “the products are legally distinct with certain differences . . .” Id. (emphasis added). 
21. To date, no entity has revealed, nor have Plaintiffs been able to obtain, any evidence indicating what those “certain differences” may be. Despite this, the FDA asserts that the two formulations can be used interchangeably.
22. For example, in the FDA’s fact sheet6 for recipients and caregivers, for example, it reads, “The FDA-approved COMIRNATY (COVID-19 Vaccine, mRNA) and the FDA-authorized Pfizer-BioNTech COVID-19 Vaccine under Emergency Use Authorization (EUA) have the same formulation and can be used interchangeably to provide the COVID-19 vaccination series.”
23. In a press release7 announcing Pfizer’s collaboration with Brazil’s Eurofarma to manufacture COVID-19 vaccine doses, Pfizer wrote, “COMIRNATY® (COVID-19 Vaccine, mRNA) is an FDA-approved COVID-19 vaccine made by Pfizer for BioNTech” and “PfizerBioNTech COVID-19 Vaccine has received EUA from FDA.” The press release continued, stating, “This emergency use of the product has not been approved or licensed by FDA, but has been authorized by FDA under an Emergency Use Authorization (EUA) to prevent Coronavirus Disease 2019 (COVID-19) . . .”. Id.
24. Then, in a September 6, 2021 press release8 announcing a submittal to a request by the European Medicines Agency (EMA) to update its Conditional Marketing Authorization (CMA) for a booster dose, BioNTech–Pfizer’s co-partner in the production of the Pfizer-BioNTech COVID-19 vaccine–clearly states, “The Pfizer-BioNTech COVID-19 vaccine has not been approved or licensed by the U.S. Food and Drug Administration (FDA), but has been authorized for emergency use by FDA under an Emergency Use Authorization (EUA) to prevent Coronavirus Disease 2019 (COVID-19) . . .”. Id.
25. The product’s labeling is even indicative that the vaccines are distinguishable. In a letter addressed to Pfizer, the FDA stated, “The Pfizer-BioNTech COVID-19 Vaccine vial label and carton labels are clearly marked for ‘Emergency Use Authorization.’”9
26. Mindful of this new marketing change, the FDA included specific language in its August 23 letter to Pfizer distinguishing the two vaccines, stating “the licensed vaccine (COMIRNATY) has the same formulation as the EUA-authorized vaccine (Pfizer-BioNTech) and the products can be used interchangeably to provide the vaccination series without presenting any safety or effectiveness concerns.” Id. This is not true.
27. According to the CDC, “the FDA approved the licensure of COMIRNATY (COVID-19 Vaccine, mRNA), made by Pfizer for BioNTech.”10 The FDA did not approve the Pfizer-BioNTech vaccine. Despite full knowledge that the BioNTech vaccine is not FDAapproved, the CDC nevertheless stated that, because “[t]he FDA-approved Pfizer-BioNTech product COMIRNATY and the FDA-authorized Pfizer-BioNTech COVID-19 vaccine have the same formulation[,] [the two vaccines] can be used interchangeably to provide the COVID-19 vaccination series . . .”. As a result, the CDC has advised:
[V]accination providers can use doses distributed under EUA [(e.g., the non-FDA approved Pfizer-BioNTech vaccine)] to administer the vaccination series as if the doses were the licensed vaccine.11
28. The CDC is wrong. The EUA statute, 21 U.S.C. § 360bbb-3, explicitly states that anyone to whom an EUA product is administered must be informed of the option to accept or to refuse it, as well as alternatives to the product and the risks and benefits of receiving it. 
29. The CDC’s erroneous assertion th
...[Message truncated]
View Full Message